Biotech News
Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies
ABILITY-1 is evaluating MDNA11, a “not-alpha beta-enhanced” IL-2 Superkine, either alone or in combination with pembrolizumab, in advanced solid tumors resistant to approved therapies Achieved 40% objective response rate (ORR; 8/20) and 80% disease control rate (DCR; 16/20) across
